NCT07537985: Efficacy and Safety Comparison Between PD-1 Inhibitor Combined With Lenvatinib or With Regorafenib For UHCC After Failure of First-line Treatment

Sponsor: Sun Yat-sen University. Phase: NA. Conditions: Hepatocellulcar Carcinoma